全球能力细胞市场规模（按应用、类型、最终用户、地区、范围和预测）

感受态细胞市场规模及预测

预计 2024 年感受态细胞市场规模将达到 19.1 亿美元，2031 年将达到 40.4 亿美元，2024-2031 年预测期内的复合年增长率为 9.80%。

推动全球感受态细胞市场的因素

感受态细胞市场的市场推动因素受到多种因素的影响。

研发活动：

生物技术和分子生物学研究的进步推动了对感受态细胞的需求。

生物製药领域的成长：

不断扩大的生物製药市场推动了对用于生产治疗性蛋白质、抗体和疫苗等生物製药的感受态细胞的需求日益增长。

增加生命科学投资：

对生命科学研究的投资，特别是在合成生物学、基因组学和个人化医疗等领域的投资，正在促进感受态细胞市场的扩大，因为这些领域主要依赖分子克隆方法。

对重组DNA技术的需求日益增加：

重组 DNA 技术已被广泛应用于基因编辑、基因治疗和基因改造生物 (GMO) 的创造等各种应用，该技术严重依赖感受态细胞。

技术开发：

市场发展将受到细胞转化方法技术持续发展的推动，包括提高转化效率和生成与各种克隆载体相容的新型感受态细胞系。

CRISPR 技术的快速应用：

CRISPR/Cas9 基因编辑技术在治疗和研究环境中的应用日益广泛，推动了对适合基于 CRISPR 的研究的感受态细胞的需求。

个人化医疗的需求日益增长：

基因编辑和基因治疗应用需要感受态细胞。个人化医疗的趋势取决于我们瞭解每个人独特基因组成的能力。

环境和永续性问题：

人们对环境永续性和绿色技术需求的日益关注推动了用于生产生物基产品和环境友善製程的感受态细胞的需求。

新兴市场：

由于对生物技术研究的投资不断增加以及生物製药製造能力的发展，亚太地区、拉丁美洲和中东的新兴市场具有巨大的成长潜力。

监管状况：

随着公司为其研究和製造流程寻求合规解决方案，基因改造作物 (GMO) 的使用和生物製药开发受到法规的约束，这些法规影响了对感受态细胞的需求。

限制全球感受态细胞市场的因素

感受态细胞市场面临多种限制和课题。这些包括：

成本高：

开发感受态细胞的成本很高，因为它需要特定的材料和复杂的製造技术。这可能使资源较少的组织或规模较小的实验室难以获得感受态细胞。

技术限制：

儘管取得了进展，但仍存在影响感受态细胞的有效性和可靠性的技术障碍。感受态细胞的性能会受到稳定性、与各种 DNA 构建体的兼容性以及转化效率等因素的影响。

监管障碍：

生产和销售感受态细胞的公司可能会面临课题，因为对于使用基因改造生物 (GMO) 和工程细胞有严格的规定和监督。法规遵从性增加了开发和商业化过程的复杂性和成本。

衝突：

感受态细胞产业竞争相当激烈，许多老牌公司和新进者都提供类似的产品。价格和利润率可能因竞争而下降，使得企业更难脱颖而出并维持市场占有率。

道德问题：

基因改造生物的使用可能会引发伦理问题，尤其是在某些地区和经济领域。公众舆论和监管机构对基因改造生物的看法可能会影响市场对我们的感受态细胞产品的需求和接受度。

供应链中断：

生产流程的变化或原材料的短缺可能会扰乱供应链，影响熟练劳动力的可用性并影响定价和市场稳定。

限量招募：

儘管感受态细胞具有许多优点，但一些实验室可能不愿意使用它们，因为担心工作流程整合、需要专门的技术知识以及重组基因技术相关的风险。

目录

第1章 全球感受态细胞市场简介

• 市场概况
• 调查范围
• 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章 感受态细胞的全球市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析
• 监管框架

第5章 全球感受态细胞市场（依应用）

• 概述
• 复製
  • 亚克隆和常规克隆
  • 噬菌体展示文库构建
  • 有毒/不稳定 DNA 克隆
  • 高通量克隆
• 蛋白质表现
• 其他
  • 突变介绍
  • 大型质粒转化
  • 单股 DNA 生成
  • 慢病毒载体生产

第6章 全球感受态细胞市场依类型

• 概述
• 化学感受态细胞
• 电感受态细胞

第 7 章 全球感受态细胞市场（依最终用户划分）

• 概述
• 学术研究所
• 製药和生物技术公司
• 合同研究所

第 8 章 全球感受态细胞市场（按地区）

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第9章全球感受态细胞市场：竞争格局

• 概述
• 企业市占率
• 供应商情况
• 主要发展策略

第10章 公司简介

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio, Inc.
• New England Biolabs, Inc.
• Bio-Rad Laboratories, Inc.
• Transgen Biotech, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Zymo Research
• Qiagen N.V.
• Genscript Biotech Corporation
• Origene Technologies, Inc.

第 11 章 附录

• 相关报导

Competent Cells Market Size And Forecast

Competent Cells Market size was valued at USD 1.91 Billion in 2024 and is projected to reach USD 4.04 Billion by 2031, growing at a CAGR of 9.80% during the forecasted period 2024 to 2031.

Global Competent Cells Market Drivers

The market drivers for the Competent Cells Market can be influenced by various factors. These may include:

Research and Development Activities:

The need for competent cells is driven by advances in biotechnology and molecular biology research, as these cells are necessary for a variety of molecular cloning and gene expression studies.

Increase in the Biopharmaceutical Sector:

The need for competent cells to produce biopharmaceuticals-such as therapeutic proteins, antibodies, and vaccines-is fueled by the growing market for these biologics.

Rising Life Sciences Investments:

Since these areas mostly rely on molecular cloning methods, investments in life sciences research-particularly in areas like synthetic biology, genomics, and personalized medicine-contribute to the market expansion of competent cells.

Growing Need for Technology Using Recombinant DNA:

Recombinant DNA technology, which is widely employed in many different applications like gene editing, gene therapy, and the creation of genetically modified organisms (GMOs), depends heavily on competent cells.

Technological Developments:

Market expansion is fueled by ongoing technological developments in cell transformation methods, such as the creation of novel competent cell strains with enhanced transformation efficiency and compatibility with various cloning vectors.

Rapid CRISPR Technology Adoption:

The increasing use of CRISPR/Cas9 gene editing technology in therapeutic and research settings raises the need for competent cells appropriate for CRISPR-based studies.

The Need for Personalized Medicine Is Increasing:

Competent cells are necessary for gene editing and gene therapy applications because of the trend toward personalized treatment, which depends on our ability to understand each person's unique genetic composition.

Concerns for the Environment and Sustainability:

The demand for competent cells employed in the creation of bio-based goods and environmentally friendly processes is driven by the growing concerns about environmental sustainability and the need for green technology.

Emerging Markets:

As a result of rising investments in biotechnology research and developing biopharmaceutical manufacturing capacities, emerging markets in Asia-Pacific, Latin America, and the Middle East offer substantial growth prospects.

Regulatory Landscape:

As businesses look for compliance solutions for their research and manufacturing processes, the usage of genetically modified organisms (GMOs) and the development of biopharmaceuticals are subject to regulations that impact the demand for competent cells.

Global Competent Cells Market Restraints

Several factors can act as restraints or challenges for the Competent Cells Market. These may include:

High Cost:

Developing competent cells can be expensive due to the need for specific materials and complex manufacturing techniques. This may make them less accessible to organizations with fewer finances or smaller research labs.

Technological Limitations:

Despite developments, there may still be technological barriers that affect the effectiveness and dependability of competent cells. Their performance can be affected by factors like stability, compatibility with different DNA constructions, and transformation efficiency.

Regulatory Obstacles:

Businesses that produce and distribute competent cells may face difficulties due to strict rules and oversight around the use of genetically modified organisms (GMOs) or altered cells. Regulation adherence increases the process of development and commercialization's complexity and expense.

Competition:

A number of well-established businesses and recent entrants provide comparable goods in the competent cells industry, which is reasonably competitive. Prices and profit margins may decline due to competition, making it difficult for businesses to stand out from the competition and hold onto market share.

Ethical Concerns:

The use of genetically modified organisms may raise ethical questions, particularly in some areas or sectors of the economy. Market demand and acceptability of competent cell products can be influenced by public and regulatory views on genetically modified organisms.

Supply Chain Disruptions:

Changes in the production process or a scarcity of raw materials can cause supply chain disruptions that affect the availability of skilled labor and affect pricing and market stability.

Limited Adoption:

Although competent cells have many advantages, some research labs may be reluctant to use them because of worries about workflow integration, the need for specialized technical knowledge, or perceived hazards related to genetic modification methods.

Global Competent Cells Market: Segmentation Analysis

The Global Competent Cells Market is segmented on the basis of Application, Type, End User, And Geography.

Competent Cells Market, By Application

• Cloning
• Subcloning& Routine Cloning
• Phage Display Library Construction
• Toxic/Unstable DNA Cloning
• High-Throughput Cloning
• Protein Expression
• Others
• Mutagenesis
• Large Plasmid Transformation
• Single-Stranded DNA Production
• Lentiviral Vector Production

Based on Application, the market is bifurcated into Cloning, Protein Expression, and Others. The Cloning segment is expected to hold the largest market share. The factors can be attributed to the growing research on cloning driven by government support and funding.

Competent Cells Market, By Type

• Chemically Competent Cells
• Electro Competent Cells

Based on Type, the market is bifurcated into Chemically Competent Cells and Electro Competent Cells. The Chemically Competent Cells segment is predicted to hold the largest market share in the forecasted period. The Electro Competent Cells segment is anticipated to grow with the highest CAGR as Electro Competent Cells are suitable for many molecular biology applications like the generation of cDNA libraries as they possess high transformation efficiencies.

Competent Cells Market, By End User

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

Based on End User, the market is bifurcated into Academic Research Institutes, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations. The Pharmaceutical & Biotechnology Companies segment is anticipated to hold the largest market share. The factors can be credited for increasing investments in research for developing genomics and proteomics-based products.

Competent Cells Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Competent Cells Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of R&D activities in this region.

Key Players

• The major players in the Competent Cells Market are:
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio Inc.
• New England Biolabs Inc.
• Bio-Rad Laboratories Inc.
• Transgen Biotech Inc.
• Agilent Technologies Inc.
• Illumina Inc.
• Zymo Research
• Qiagen N.V.
• Genscript Biotech Corporation
• and Origene Technologies Inc.
• Thermo Fisher Scientific
• Merck KGaA
• New England Biolabs
• Takara Bio
• Agilent Technologies

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COMPETENT CELLS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COMPETENT CELLS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL COMPETENT CELLS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Cloning
  • 5.2.1 Subcloning& Routine Cloning
  • 5.2.2 Phage Display Library Construction
  • 5.2.3 Toxic/Unstable DNA Cloning
  • 5.2.4 High-Throughput Cloning
• 5.3 Protein Expression
• 5.4 Others
  • 5.4.1 Mutagenesis
  • 5.4.2 Large Plasmid Transformation
  • 5.4.3 Single-Stranded DNA Production
  • 5.4.4 Lentiviral Vector Production

6 GLOBAL COMPETENT CELLS MARKET, BY TYPE

• 6.1 Overview
• 6.2 Chemically Competent Cells
• 6.3 Electro Competent Cells

7 GLOBAL COMPETENT CELLS MARKET, BY END USER

• 7.1 Overview
• 7.2 Academic Research Institutes
• 7.3 Pharmaceutical & Biotechnology Companies
• 7.4 Contract Research Organizations

8 GLOBAL COMPETENT CELLS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL COMPETENT CELLS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck KGaA
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Promega Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Takara Bio, Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 New England Biolabs, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bio-Rad Laboratories, Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Transgen Biotech, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Agilent Technologies, Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Illumina, Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Zymo Research
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Qiagen N.V.
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Genscript Biotech Corporation
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Origene Technologies, Inc.
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments

11 Appendix

• 11.1 Related Reports